Edgewise Therapeutics, Inc. (EWTX) Profit Breakdown
- 2026-06-30: Single reportable segment -$57.33M.
- 2025-06-30: Single reportable segment -$36.12M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2020-03-31 to 2026-06-30
- Data captured
Profit by product
Net Income (Loss) Attributable to Parent: each quarter (3 month)
| Quarter end | Single reportable segment |
|---|---|
| 2026-06-30 | -$57.33M |
| 2025-06-30 | -$36.12M |
Operating income: each quarter (3 month)
| Quarter end | Single reportable segment |
|---|---|
| 2026-06-30 | -$61.94M |
| 2025-06-30 | -$42.61M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |